All In Biotech

NDA 213716 · Aurinia

Lupkynis

Voclosporin · Oral · Calcineurin Inhibitor Immunosuppressant

NovelPriority review

CDER novel approval, Jan 22, 2021: To treat lupus nephritis

Last checked: Nov 19, 2026Latest source record: Oct 8, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2021

Jan 22, 2021

Approved uses

2

Original approval plus efficacy supplements

Registered trials

24

11 Phase 3, 5 recruiting

FAERS reports

9,788

1,987 serious, 61 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: MALIGNANCIES AND SERIOUS INFECTIONS Increased risk for developing malignancies and serious infections with LUPKYNIS or other immunosuppressants that may lead to hospitalization or death [see Warnings and Precautions ( 5.1 , 5.2 )]. WARNING: MALIGNANCIES AND SERIOUS INFECTIONS See full prescribing information for complete boxed warning. Increased risk for developing serious infections and malignancies with LUPKYNIS or other immunosuppressants that may lead to hospitalization or death. ( 5.1 , 5.2 )

What it is approved for

From the label in effect Nov 11, 2026.

LUPKYNIS is indicated in combination with a background immunosuppressive therapy regimen [see Clinical Studies ( 14 )] for the treatment of adult patients with active lupus nephritis (LN). Limitations of Use: Safety and efficacy of LUPKYNIS have not been established in combination with cyclophosphamide. Use of LUPKYNIS is not recommended in this situation. LUPKYNIS is a calcineurin-inhibitor immunosuppressant indicated in combination with a background immunosuppressive therapy regimen for the treatment of adult patients with active lupus nephritis (LN). ( 1 , 14 ) Limitations of Use: Safety and efficacy of LUPKYNIS have not been established in combination with cyclophosphamide. Use of LUPKYNIS is not recommended in this situation.

Mechanism: LUPKYNIS is a calcineurin-inhibitor immunosuppressant. The mechanism of voclosporin suppression of calcineurin has not been fully established. Activation of lymphocytes involves an increase in intracellular calcium concentrations that bind to the calcineurin regulatory site and activate calmodulin binding catalytic subunit and through dephosphorylation activates the transcription factor, Nuclear Factor of Activated T-Cell Cytoplasmic (NFATc). The immunosuppressant activity results in inhibition of lymphocyte proliferation, T-cell cytokine production, and expression of T-cell activation...

Therapeutic areas: Immunology and inflammation · Kidney and urology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Apr 29, 2024 Supplement 4 · Efficacy LetterLabel
  • Jan 22, 2021 Original approval · Type 1 - New Molecular Entity · priority review NovelLetterLabelReview
1 products under this application
  • LUPKYNIS · VOCLOSPORIN 7.9MG · CAPSULE, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Voclosporin" as an intervention, any sponsor and status, largest first.

All 24 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • therapy interrupted991
  • product dose omission issue870
  • hypertension807
  • headache764
  • nausea715
  • fatigue625
  • diarrhoea605
  • proteinuria557
  • blood pressure increased440
  • product use issue427
  • glomerular filtration rate decreased380
  • vomiting369

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20191
2021431
20221,006
20231,506
20242,002
20252,316
20262,526

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Lupkynis (Voclosporin)

2024 spending

$25.8M

Beneficiaries

339

2,078 claims

Per beneficiary

$75,988

$81.70 per unit

View as table
YearSpending
2020$0
2021$4,067,190
2022$12,639,888
2023$20,169,855
2024$25,759,784

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 24 on PubMed

Sponsor: Aurinia

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.